Get a quick, expert overview of risk management in transfusion medicine from Dr. James Mills Barbeau. This practical resource presents a summary of today’s state-of-the-art techniques for reducing harm during all phases of transfusion practice, including blood collection, testing, processing, clinical assessment, and transfusion. It’s an easy-to-read, one-stop resource for managing and mitigating the various levels of risk in a variety of transfusion settings and scenarios. Presents a well-rounded perspective on quality assurance, blood supply testing, clinical risk, ethical and legal considerations, and transfusion-transmitted infectious diseases. Demonstrates how transfusion risk-management programs add value to health care institutions by enhancing a culture of safety, improving the institution’s reputation, and improving the bottom line. Consolidates today’s available information on risk management in blood transfusion medicine into one convenient resource.
How Much Blood Is Transfused?WHO IS BEING TRANSFUSED?; WHY IS BLOOD TRANSFUSED?; EARLY STEPS TO IMPROVE PHYSICIAN PRESCRIBING PRACTICES; AUDITING AND MONITORING PHYSICIAN PRESCRIBING PRACTICES; Providing Physician Feedback; CONCLUSION; Appendix: Red Cell Transfusion inNormovolemic Anemia; RED CELL TRANSFUSION IN NORMOVOLEMIC INPATIENTS; WHAT IS NORMOVOLEMIC ANEMIA?; I'VE SEEN OTHER PHYSICIANS ORDER 2 UNITS OF RED CELLS FOR THESE PATIENTS. WHAT WRONG WITH THIS?; WHY SHOULD I WAIT 4-6H?; WHAT ABOUT OUTPATIENTS?; WHAT ARE THE DATA?
|Pages||: 329 pages|
|Author||: C.Th. Smit Sibinga,H.J. Alter|
|Publisher||: Springer Science & Business Media|
|Release Date||: 2013-06-29|
|ISBN 10||: 1475730098|
|Pages||: 236 pages|
Mr. Chairman, ladies and gentlemen, with great pleasure I like to welcome you in the cityofGroningen and hope that you will have an enriching and enlighten ing discussion on the conference theme on risk management in blood trans fusion. The organisation of this symposium aims at scientific networking by discussing in an international forum the most important themes of current interest in relation to the state of the art in transfusion medicine. Dr. Cees Smit Sibinga took the initiative in 1976 to start organising the blood bank symposia as they were named in the beginning. Without doubt these symposia have contributed considerably to the development of transfusion medicine. To illustrate the fact that these symposia came to my attention I recollect that I have attended the symposium in 1978, chaired by Dr. Leo Vroman, in my capacity in those days of alderman deputy mayor of the city. So, it has been a long time since. After having been away from Groningen for 18 years I have been inaugurated last week as a mayor and it is a plcasure to be again in your midst. The scries of annual symposia on blood transfusion have contributed to mark the city of Groningen on the map of the international scientific world. A great number of prestigious institutes all over the world involved in the development of transfusion medicine have linked to Groningen and we are proud of that.
|Author||: American Society for Healthcare Risk Management. Conference|
|Release Date||: 1997|
|Pages||: 329 pages|
It is an honour and a pleasure to welcome you all at this 20th annual International Symposium on Blood Transfusion in the Netherlands. This year you celebrate its 20th anniversary and I congratulate the Staff of the Blood Bank Noord Nederland and especially Dr. Smit Sibinga for this great achievement. As most of you know, the name of the person of Dr. Smit Sibinga is unbreakably con nected with the annual symposium in Groningen which he has organized each year from the very start, 20 years ago. The reputation of any symposium depends heavily on the quality of the lectures. I think it is not possible to organize 20 symposia in a row if the topics lack actual relevance and the speakers are not of excellent reputation. Dr. Smit Sibinga has proven to have a keen eye for selecting interesting themes and eminent speakers. Although a lot of different topics have been dealt with in the past 20 years, which each attracted the attention of a different group in the field of blood transfusion, it is not surprising that after a tradition of 20 years several speakers but also a lot of attendees are not for the first time in Groningen to participate in this event. It gives the symposium a unique atmosphere of intimacy. It is not hard to admit that most of the newer developments in transfusion medicine take place outside the Netherlands.
Patient Blood Management (PBM) is an innovative clinical concept that aims to reduce the need for allogenic blood transfusions, cut health-care costs, and avert or correct the risk factors related to blood transfusion, thus minimizing the rate of side effects and complications. This comprehensive hands-on volume offers a three-point approach for the implementation of PBM to improve patient outcome, focusing on how to prevent or treat anemia, reduce blood loss, and increase anemia tolerance. The book also goes beyond preoperative PBM, with detailed accounts of coagulation disorder management and the administration of coagulation products and platelet concentrates. Special Features: Presents a clear three-pillar strategy for the application of PBM: diagnosis and treatment of anemia, reduction of peri-interventional blood loss, and optimization of the tolerance to anemia in the everyday clinical setting Covers issues such as PBM during surgery, requirements for modern transfusion medicine, ordering blood products, the role of pre-anesthesia clinics, benchmarking processes, and potential implications of PBM in the public health sector Overview of research in PBM including landmark studies and current clinical trials Boxes in each chapter highlighting key information, core statements, and summaries A multidisciplinary and international team of contributors experienced in PBM Patient Blood Management is a guide for clinicians and residents whose patients are at risk for anemia, coagulation disorders, or severe blood loss. Anesthesiologists, surgeons, and specialists involved in the use of blood and blood products can use the book for quick reference or to learn more about a leading-edge concept for optimizing patient safety and improving outcome.
Structured to be a companion to the recently published Handbook of Transfusion Medicine, the Handbook of Pediatric Transfusion Medicine is dedicated to pediatric hematology-oncology and transfusion medicine, a field which remains ambiguous and which has generated few comprehensive texts. This book stands alone as one of the few texts that addresses transfusion issues specific to pediatric medicine. Written in an eminently readable style, this authoritative handbook is a requirement for any pediatric physician or caregiver. Neonatal and fetal immune response and in utero development issues Blood compatability and pre-transfusion testing issues specific to pediatric and neonatal transfusion Therapeutic apheresis including red blood cell exchange and prophylactic chronic erythrocytapheresis for sickle cell patients Also includes a section that concentrates on the consent, quality and legal issues of blood transfusion and donation
The WHO guidelines on assessing donor suitability for blood donation have been developed to assist blood transfusion services in countries that are establishing or strengthening national systems for the selection of blood donors. They are designed for use by policy makers in national blood programmes in ministries of health, national advisory bodies such as national blood commissions or councils, and blood transfusion services.
During the early years of the AIDS epidemic, thousands of Americans became infected with HIV through the nation's blood supply. Because little reliable information existed at the time AIDS first began showing up in hemophiliacs and in others who had received transfusions, experts disagreed about whether blood and blood products could transmit the disease. During this period of great uncertainty, decisionmaking regarding the blood supply became increasingly difficult and fraught with risk. This volume provides a balanced inquiry into the blood safety controversy, which involves private sexual practices, personal tragedy for the victims of HIV/AIDS, and public confidence in America's blood services system. The book focuses on critical decisions as information about the danger to the blood supply emerged. The committee draws conclusions about what was done--and recommends what should be done to produce better outcomes in the face of future threats to blood safety. The committee frames its analysis around four critical area Product treatment--Could effective methods for inactivating HIV in blood have been introduced sooner? Donor screening and referral--including a review of screening to exlude high-risk individuals. Regulations and recall of contaminated blood--analyzing decisions by federal agencies and the private sector. Risk communication--examining whether infections could have been averted by better communication of the risks.